Sanofi Ventures leads $17M investment in Click Therapeutics, finalist @ 2017 Brainnovations Pitch Contest
Conclusions: In this initial single-arm trial, Clickotine users appeared to demonstrate encouraging indicators of engagement in terms of the number of app opens, number of program interactions, and continued engagement over time. Clickotine users reported encouraging quit rates while reporting few adverse events. Future research is warranted to assess Clickotine’s efficacy in a randomized controlled trial.
The News in Context:
Pear Therapeutics raises $50M to develop and market a portfolio of digital therapeutics for mental health
10 neurotechnologies about to transform brain enhancement and brain health
Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
Heads-up: The 2018 SharpBrains Virtual Summit (December 4–6th, 2018) will feature over forty of the world’s top experts, innovators and investors aiming to improve brain health and performance for all in light of growing neuroscience and digital tech.
Presentation by David Klein, CEO of Click Therapeutics, during the 2017 Brainnovations Pitch Contest:
?
Top Brainnovation to improve Brain Health & Performance from SharpBrains
Source: SharpBrains - Category: Neuroscience Authors: SharpBrains Tags: Cognitive Neuroscience Health & Wellness Technology Brainnovations cigarette smoking Click Therapeutics Clickotine digital medicine digital therapeutics Pear Therapeutics Sanofi Ventures smartphone smoking cessation tobacco Source Type: blogs
More News: Brain | Clinical Trials | Depression | France Health | Insomnia | Men | Neurology | Neuroscience | Smokers | Study | USA Health | Venture Capital